Abstract 1862P
Background
Cancer related fatigue (CRF) is a common side effect of cancer and cancer treatment that impacts every aspect of quality of life. To our knowledge, the statistics for prevalence in pediatrics are lacking in Egypt. The aim of this study is to record the prevalence of fatigue and its significant predicting factors in pediatric oncology patients.
Methods
We interviewed children aged 8-18 years with cancer, prescribed chemotherapy and not in severe distress. After the consent of the guardian is taken, the children personally filled 2 fatigue-related questionnaires (PROMIS Pediatric Short Forms of Fatigue (PROMIS fatigue), pedsQL multidimensional fatigue (PedsQL fatigue)) and 3 symptoms related questionnaires.
Results
42 children (47.6% female) (mean age 12.1 years (SD 3.3 years)) participated. Half of the children were in primary school (n=21, 50%) and most of them had their parents accompanying them (n=35, 83.3%). Most children suffered from a hematological tumor (n=35, 83.3%) and didn’t suffer from other chronic health conditions (n=39, 92.8%). Reported moderate to severe fatigue in children is between half to third of the children depending on the measurement tool used. The mean T-score for PROMIS fatigue was 53.76 (SD 12.5), the mean score for PedsQL fatigue was 74.27 (SD 21.79). Stepwise standardized multivariant linear regression showed that fatigue following PROMIS fatigue could be predicted by depressive symptoms.
Conclusions
CRF is multifactorial and prevalent among children and adolescents with cancer. Moreover, predicting factors differed between different tools as they measure fatigue from different dimensions. PedsQL fatigue was predicted by more factors. There is a need to include fatigue screening for pediatric oncology patients and incorporate its management in the medical care plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05